Literature DB >> 31239121

Therapeutic strategies for type 2 diabetes mellitus in women after menopause.

Stavroula A Paschou1, Ljiljana V Marina2, Eleftherios Spartalis3, Panagiotis Anagnostis4, Andreas Alexandrou5, Dimitrios G Goulis4, Irene Lambrinoudaki6.   

Abstract

As type 2 diabetes mellitus (T2DM) is affected by both chronological and ovarian ageing, it is common in postmenopausal women. This review analyses and critically appraises the literature regarding the optimal therapeutic strategies for T2DM in women after menopause. Lifestyle interventions, including changes in dietary habits and physical exercise in everyday life targeting a modest weight loss (5%), represent the cornerstone of management. Limited intake of alcohol and sodium, as well as smoking cessation, are additional lifestyle changes for both endothelial and bone health. Regarding medications, postmenopausal women should be initially treated with metformin, concurrently with lifestyle intervention. If glycosylated haemoglobin (HbA1c) remains over the target level (usually ≥7%), dipeptidyl peptidase-4 inhibitors (DPP-4i) or glucagon-like peptide-1 receptor agonists (GLP-1RA) should be preferred. Thiazolidinediones (TZDs) and canagliflozin should be avoided in postmenopausal women with increased fracture risk. Insulin should be used with caution to avoid hypoglycaemia. Bariatric surgery is a well established and effective therapeutic option for both weight loss and glycaemic control in very obese patients with T2DM; however, metabolic benefits should be balanced against nutritional deficiencies that often present after surgery. Proper control of hypertension, with avoidance of hypotension, is of great importance as a measure against falls. Annual tests for retinopathy and neuropathy are crucial for the same reason. Menopausal hormone therapy (MHT) has a beneficial effect on glucose homeostasis, reduces the risk of new-onset T2DM and improves glucose control in women with T2DM. T2DM has been considered a cardiovascular disease equivalent, which meant that postmenopausal women with the disease could not take MHT but current evidence supports an individualised approach to this issue. Therapeutic strategies for women with T2DM after menopause should aim to maximise benefits for metabolic, cardiovascular and bone health with the minimum of adverse effects, bearing in mind that most women will spend more than one-third of their life being of postmenopausal status.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anti-diabetic medications; Hormone replacement therapy; Menopausal hormone therapy; Menopause; Type 2 diabetes mellitus

Mesh:

Substances:

Year:  2019        PMID: 31239121     DOI: 10.1016/j.maturitas.2019.05.003

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  8 in total

Review 1.  The interplay between diabetes mellitus and menopause: clinical implications.

Authors:  Irene Lambrinoudaki; Stavroula A Paschou; Eleni Armeni; Dimitrios G Goulis
Journal:  Nat Rev Endocrinol       Date:  2022-07-07       Impact factor: 47.564

2.  Investigation of the Therapeutic Potential of New Antidiabetic Compounds Using Islet-on-a-Chip Microfluidic Model.

Authors:  Patrycja Sokolowska; Elzbieta Jastrzebska; Agnieszka Dobrzyn; Zbigniew Brzozka
Journal:  Biosensors (Basel)       Date:  2022-05-05

3.  The cardiometabolic benefits of exercise in postmenopausal women.

Authors:  Steven G Chrysant
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-09-10       Impact factor: 3.738

4.  Physical activity is associated with lower arterial stiffness in normal-weight postmenopausal women.

Authors:  Kimon Stamatelopoulos; Nikolaos Tsoltos; Eleni Armeni; Stavroula A Paschou; Areti Augoulea; Georgios Kaparos; Demetrios Rizos; Iliana Karagouni; Dimitris Delialis; Sophia Ioannou; Michail Apostolakis; Evangelos Makrakis; Irene Lambrinoudaki
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-08-20       Impact factor: 3.738

5.  Type 2 Diabetes Mellitus and Menopausal Hormone Therapy: An Update.

Authors:  Stavroula A Paschou; Nikolaos Papanas
Journal:  Diabetes Ther       Date:  2019-09-24       Impact factor: 2.945

6.  Type 2 diabetes mellitus in women with polycystic ovary syndrome during a 24-year period: importance of obesity and abdominal fat distribution.

Authors:  M Forslund; K Landin-Wilhelmsen; P Trimpou; J Schmidt; M Brännström; E Dahlgren
Journal:  Hum Reprod Open       Date:  2020-01-15

7.  Low Reported Adherence to the 2019 American Diabetes Association Nutrition Recommendations among Patients with Type 2 Diabetes Mellitus, Indicating the Need for Improved Nutrition Education and Diet Care.

Authors:  Savvas Katsaridis; Maria G Grammatikopoulou; Konstantinos Gkiouras; Christos Tzimos; Stefanos T Papageorgiou; Anastasia G Markaki; Triada Exiara; Dimitrios G Goulis; Theodora Papamitsou
Journal:  Nutrients       Date:  2020-11-15       Impact factor: 5.717

Review 8.  Maximizing the Estrogenic Potential of Soy Isoflavones through the Gut Microbiome: Implication for Cardiometabolic Health in Postmenopausal Women.

Authors:  Lindsay M Leonard; Mun Sun Choi; Tzu-Wen L Cross
Journal:  Nutrients       Date:  2022-01-27       Impact factor: 5.717

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.